Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy [8]

Annals of Internal Medicine

Volumn 145, Issue 3, 2006, Pages 234-235

  Swaminathan, Sundararaman ^a   Ahmed, Iftikhar ^a   McCarthy, James T ^a   Albright, Robert C ^a   Pittelkow, Mark R ^a   Caplice, Noel M ^a   Griffin, Matthew D ^a   Leung, Nelson ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; LETTER; MALE; NEPHROGENIC FIBROSING DERMOPATHY; PRIORITY JOURNAL; SURVIVAL; FIBROSIS; KIDNEY FAILURE; PATHOLOGY; SKIN DISEASE;

ERYTHROPOIETIN, RECOMBINANT; FIBROSIS; HUMANS; RENAL INSUFFICIENCY; SKIN DISEASES;

EID: 33746823044     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-145-3-200608010-00021     Document Type: Letter

References (7)

1. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15:785-90.
2. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis. 1997;30:S192-240.
3. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients [Letter]. Lancet. 2000;356:1000-1.
4. LeBoit PE. What nephrogenic fibrosing dermopathy might be [Editorial]. Arch Dermatol. 2003;139:928-30.
5. Macdougall IC. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant. 2005;20 Suppl 4:iv9-15.
6. Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant. 2001;16 Suppl 7:25-8.
7. Haroon ZA, Amin K, Jiang X, Arcasoy MO. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol. 2003;163:993-1000.